CoChat

Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A

Open access

The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.

Abstract

Significance: Myostatin and activin A are secreted signaling molecules that act to limit skeletal muscle growth. Here, we show that myostatin and activin A utilize four receptor components to signal directly to muscle fibers. These findings have implications for strategies to target this signaling pathway for clinical applications to treat patients with muscle loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.2019263117

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Effect of targeting type II and type I receptors in myofibers on muscle weights. (A and B) Relative weights of pectoralis (red), triceps (gray), quadriceps (blue), and gastrocnemius/plantaris (green) muscles in mice in which Acvr2 and/or Acvr2b (A) or Alk4 and/or Alk5 (B) were targeted. Numbers are expressed as percent increase/decrease relative to the same receptor genotypes but in the absence of Myl1-cre. (C) Gastrocnemius/plantaris muscle weights of individual wild-type C57BL/6 and Mstn−/− mice or individual mice in which Acvr2/Acvr2b or Alk4/Alk5 were targeted in myofibers. Bars indicates mean values. (D) Relative muscle weights of mice in which an individual type II receptor (Acvr2 or Acvr2b) was targeted along with an individual type I receptor (Alk4 or Alk5). (E and F) Relative muscle weights of mice in which an individual type II or type I receptor was targeted along with Cfc1b (E) or Mstn (F). Numbers are expressed as percent increase/decrease relative to the same receptor genotypes but in the absence of Myl1-cre, and the color code is the same as in A and B. The numbers shown in A, B, D, and F were calculations based on muscle weights shown in Tables 1–3, which also contain the numbers of mice in each group. aP < 0.001 vs. cre−; bP < 0.01 vs. cre−; cP < 0.05 vs. cre−; dP < 0.001 vs. Mstn fl/fl, cre+; eP < 0.01 vs. Mstn fl/fl, cre+; fP < 0.05 vs. Mstn fl/fl, cre+.
Fig. 1. Effect of targeting type II and type I receptors in myofibers on muscle weights. (A and B) Relative weights of pectoralis (red), triceps (gray), quadriceps (blue), and gastrocnemius/plantaris (green) muscles in mice in which Acvr2 and/or Acvr2b (A) or Alk4 and/or Alk5 (B) were targeted. Numbers are expressed as percent increase/decrease relative to the same receptor genotypes but in the absence of Myl1-cre. (C) Gastrocnemius/plantaris muscle weights of individual wild-type C57BL/6 and Mstn−/− mice or individual mice in which Acvr2/Acvr2b or Alk4/Alk5 were targeted in myofibers. Bars indicates mean values. (D) Relative muscle weights of mice in which an individual type II receptor (Acvr2 or Acvr2b) was targeted along with an individual type I receptor (Alk4 or Alk5). (E and F) Relative muscle weights of mice in which an individual type II or type I receptor was targeted along with Cfc1b (E) or Mstn (F). Numbers are expressed as percent increase/decrease relative to the same receptor genotypes but in the absence of Myl1-cre, and the color code is the same as in A and B. The numbers shown in A, B, D, and F were calculations based on muscle weights shown in Tables 1–3, which also contain the numbers of mice in each group. aP < 0.001 vs. cre−; bP < 0.01 vs. cre−; cP < 0.05 vs. cre−; dP < 0.001 vs. Mstn fl/fl, cre+; eP < 0.01 vs. Mstn fl/fl, cre+; fP < 0.05 vs. Mstn fl/fl, cre+.CC BY-NC-ND · PubMed Central
Fig. 2. Lack of effect of targeting Acvr2 and Acvr2b in myofibers on muscle regeneration following chemical injury. (A–C) Distribution of myofiber CSAs (A), mean CSAs (B), and number of Pax7+ cells (C) in Acvr2 fl/fl, Acvr2b fl/fl mice with or without Myl1-cre either uninjured or 5 or 21 DPI.
Fig. 2. Lack of effect of targeting Acvr2 and Acvr2b in myofibers on muscle regeneration following chemical injury. (A–C) Distribution of myofiber CSAs (A), mean CSAs (B), and number of Pax7+ cells (C) in Acvr2 fl/fl, Acvr2b fl/fl mice with or without Myl1-cre either uninjured or 5 or 21 DPI.CC BY-NC-ND · PubMed Central
Fig. 3. Total body fat content by DXA analysis, plasma leptin levels, fasting blood glucose levels, and fasting plasma insulin levels in 1-y-old mice lacking MSTN and mice in which both type II receptors were targeted in myofibers. Numbers of mice in each group are shown underneath the bars.
Fig. 3. Total body fat content by DXA analysis, plasma leptin levels, fasting blood glucose levels, and fasting plasma insulin levels in 1-y-old mice lacking MSTN and mice in which both type II receptors were targeted in myofibers. Numbers of mice in each group are shown underneath the bars.CC BY-NC-ND · PubMed Central
Fig. 4. Effect of a high-fat diet on Mstn−/− mice and mice in which Acvr2 and Acvr2b have been targeted in myofibers. (A) Weight gain in male mice placed on a high-fat diet starting at 12 wk of age. (B and C) Fasting blood glucose levels (B) and GTTs (C) in 12 wk-old male mice on standard diets or after placement on a high-fat diet for 4 wk. In C, the numbers of mice in each group are the same as shown in A.
Fig. 4. Effect of a high-fat diet on Mstn−/− mice and mice in which Acvr2 and Acvr2b have been targeted in myofibers. (A) Weight gain in male mice placed on a high-fat diet starting at 12 wk of age. (B and C) Fasting blood glucose levels (B) and GTTs (C) in 12 wk-old male mice on standard diets or after placement on a high-fat diet for 4 wk. In C, the numbers of mice in each group are the same as shown in A.CC BY-NC-ND · PubMed Central
Fig. 5. Lack of bone effects of targeting Acvr2 and Acvr2b in myofibers. (A, Top) DXA analysis of wild-type C57BL/6 mice either uninjected (n = 9) or injected weekly with the ACVR2B/Fc decoy receptor at a dose of 10 mg/kg (n = 8) starting at 10 wk of age. (A, Bottom) DXA analysis of Acvr2 flox/flox, Acvr2b flox/flox mice with (n = 8) and without (n = 12) the Myl1-cre transgene at the same ages as in A, Top. *P < 0.05, **P < 0.001. (B) MicroCT images of femurs taken from these same mice at 16 wk of age. (C) Bone volume/total volume fraction, trabecular thickness, trabecular number, apparent density, and cortical thickness of femurs and L4 and L5 vertebrae determined by microCT analysis in these mice at 16 wk of age. Numbers of mice in each group are shown underneath the bars.
Fig. 5. Lack of bone effects of targeting Acvr2 and Acvr2b in myofibers. (A, Top) DXA analysis of wild-type C57BL/6 mice either uninjected (n = 9) or injected weekly with the ACVR2B/Fc decoy receptor at a dose of 10 mg/kg (n = 8) starting at 10 wk of age. (A, Bottom) DXA analysis of Acvr2 flox/flox, Acvr2b flox/flox mice with (n = 8) and without (n = 12) the Myl1-cre transgene at the same ages as in A, Top. *P < 0.05, **P < 0.001. (B) MicroCT images of femurs taken from these same mice at 16 wk of age. (C) Bone volume/total volume fraction, trabecular thickness, trabecular number, apparent density, and cortical thickness of femurs and L4 and L5 vertebrae determined by microCT analysis in these mice at 16 wk of age. Numbers of mice in each group are shown underneath the bars.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 59

Metadata

Authors
Lee, S.-J., Lehar, A., Liu, Y., Ly, C. H., Pham, Q.-M., Michaud, M., Rydzik, R., Youngstrom, D. W., Shen, M. M., Kaartinen, V., Germain-Lee, E. L., & Rando, T. A.
Affiliations
  • University of Connecticut (US)
  • The Jackson Laboratory for Genomic Medicine (US)
  • Stanford Medicine (US)
  • Columbia University (US)
  • University of Michigan (US)
  • Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT 06030;
  • VA Palo Alto Health Care System (US)
Corresponding author
Lee, Se-Jin
Venue
Proceedings of the National Academy of Sciences
Published
2020-11-20
Volume
117
Issue
49
Pages
30907-30917
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W3106391536
Cited by
59
References
60
Citations by year
2026: 11 · 2025: 9 · 2024: 10 · 2023: 10 · 2022: 12 · 2021: 6 · 2020: 1
FWCI
2.43
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion, cc-by-nc-nd)
Funders
HHS | National Institutes of Health (R01AR060636, R01AG052962)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
Keywords
myostatin, activin A, skeletal muscle growth, TGF-beta signaling, ACVR2, ACVR2B, ALK4, ALK5, muscle mass, fat mass, glucose metabolism, high-fat diet, satellite cells, muscle regeneration, bone mineral density
MeSH terms
Animals, Mice, Inbred C57BL, Muscles, Organ Size, Muscle Fibers, Skeletal, Muscle Development, Activins, Activin Receptors, Type I, Activin Receptors, Type II, Myostatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A. https://app.cochat.ai/papers/10.1073/pnas.2019263117
The paper
Lee, S.-J., Lehar, A., Liu, Y., Ly, C. H., Pham, Q.-M., Michaud, M., Rydzik, R., Youngstrom, D. W., Shen, M. M., Kaartinen, V., Germain-Lee, E. L., & Rando, T. A. (2020). Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2019263117

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.